Business Wire

Miller Barondess Files Lawsuit Against Nissan North America Over Alleged Scheme to Undermine Successful Automotive Dealer

28.3.2025 01:02:00 CET | Business Wire | Press release

Share

Trophy Universal City Group, LLC and Trophy West Covina Motor Group, LLC (“Trophy Group”) have filed a lawsuit against Nissan North America, Inc., accusing the automaker of orchestrating a deliberate and nefarious scheme to suffocate vehicle inventory and squeeze out the Trophy Group. The case centers on two Los Angeles County Nissan dealerships—Universal City Nissan and West Covina Nissan—led by global automotive entrepreneur and Trophy Group founder and CEO, Nasser Watar, only to face what Trophy Group alleges is retaliatory sabotage by Nissan. Trophy Group is represented by Amnon Siegel and Bryan Redfern of Miller Barondess, LLP.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250327109484/en/

A Legacy of Success and Partnership

Since Trophy Group’s founding more than ten years ago, Nasser Watar, a veteran of the automotive industry, expanded Trophy Group to operate numerous successful dealerships in Southern California, including leading brands such as Mercedes-Benz and Kia. Its dealerships rank among the top-selling in the nation for their respective brands.

In addition to his U.S. operations, Watar has played a significant role in Nissan’s international distribution, particularly in the Middle East. From 2008 to 2019, he served as Vice Chairman, President and CEO of Nissan Gulf Company, a joint venture between Nissan Motor Co., Ltd. (“Nissan Japan”) and Al-Dahana Group. During Al-Dahana’s joint venture with Nissan Japan, Watar was CEO of Al-Dahana, as well as Nissan Gulf. Under Watar’s leadership, Nissan Gulf significantly expanded Nissan’s market presence, becoming the second-largest market leader in the Middle East and the most profitable Nissan subsidiary worldwide.

Nissan’s Initial Plea for Help

In 2017, recognizing Watar’s expertise, Nissan approached him to take over two struggling Los Angeles County dealerships—Universal City Nissan and West Covina Nissan. These once-successful dealerships had fallen into financial distress under their previous owner, Sage Automotive Group. Nissan sought Watar’s leadership to restore them to profitability, and Trophy Group acquired the dealerships. Initially, the transition was positive. With Nissan’s support, Watar and his team worked diligently to rebuild the dealerships’ reputation and performance.

Retaliation Following the Ghosn Scandal

In 2018, the arrest of former Nissan Japan CEO Carlos Ghosn sparked global controversy. As details emerged, Nissan Japan sought to sever ties with individuals and entities linked to the scandal—including Watar’s former business partner at Al-Dahana. Despite no allegations against Watar himself, Nissan unilaterally terminated its Gulf distribution partnership, prompting Al-Dahana to file suit. In 2021, Al-Dahana secured a $354 million judgment against Nissan Japan in Dubai.

In response, Nissan allegedly undertook a secret retaliatory campaign against Watar and Trophy Group’s U.S. dealerships, aiming to drive them out of business. Per the complaint, Nissan systematically under-allocated vehicles to Universal City Nissan and West Covina Nissan, depriving them of essential inventory while favoring nearby competitors.

The Impact of Nissan’s Unlawful Actions

New vehicle allocation is the lifeblood of any dealership, and Nissan’s alleged actions created a devastating cycle: reduced inventory led to lower sales, which in turn resulted in further reduced allocations. Despite Watar’s repeated pleas for fair treatment, Nissan allegedly refused to provide the necessary inventory, deliberately crippling the Trophy Group’s Nissan dealerships and eventually forcing them to close their doors.

Nissan’s alleged actions have resulted in millions in damages to Trophy Group and have also deprived consumers of competitive options in the Los Angeles market. Trophy Group is pursuing all available legal remedies against Nissan for its alleged targeted campaign of economic destruction.

“Nissan’s conduct represents an abuse of power and a blatant disregard for proper and fair business practices,” said Amnon Siegel. “We will not allow Nissan to unlawfully eliminate a trusted and dedicated dealer through manipulation and bad faith and look forward to the opportunity to present our case to a jury.”

The case is Trophy Universal City Group, LLC, et al. v. Nissan North America, Inc., et al., Los Angeles County Superior Court, Case No. [pending]

About Miller Barondess, LLP:

Miller Barondess, LLP is a Los Angeles-based law firm that specializes in litigation, including trial, arbitration, and appellate proceedings in California and nationwide. The firm represents both plaintiffs and defendants across a wide range of sectors, including automotive, consumer products, private equity, securities, financial services, intellectual property, patents, licensing and branding, technology and cybersecurity, real estate, healthcare, entertainment and music, sports, insurance, retail, environmental, and government. With a reputation for winning bet-the-company litigation, the firm is frequently engaged to resolve pivotal issues before trial, and other law firms bring in Miller Barondess when their clients need a trial or appellate team.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250327109484/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye